Active monitoring vs. spontaneous reporting of antineoplastic drug–related adverse drug reactions: evidence from the Chinese hospital pharmacovigilance system

CHPS-based active monitoring improves the detection, timeliness, and predictive assessment of ADRs compared with spontaneous reporting. These findings support the integration of active monitoring into hospital pharmacovigilance systems and highlight novel safety signals requiring further validation.